Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment ...
ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the need for corticosteroid use in patients with noninfectious uveitis, according ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Yuflyma to treat hidradenitis suppurativa and uveitis in children. The expanded indications ...
Co announces a study of ankylosing spondylitis patients treated with Abbott's HUMIRA showed a decrease in the rate of uveitis flares by approx half compared to patients treated with placebo. The ...
The US Food and Drug Administration has approved the first interchangeable, high-concentration, citrate-free adalimumab biosimilar, adalimumab-ryvk (Simlandi). This is the 10th adalimumab biosimilar ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback